Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP128L Anti-PLZF Mouse mAb (2A9)

This Anti-PLZF Mouse mAb (2A9) is validated for use in Gel Shift, Immunoblotting Immunofluorescence Immunoprecipitation for the detection of PLZF.

Anti-PLZF Mouse mAb (2A9) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Promyelocytic Leukemia Zinc Finger

OP128L
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
H, M, RMMonoclonal Antibody
Description
OverviewRecognizes the ~81 kDa PLZF in myelodysplastic cells treated with A23187 (Cat. No. 100105).
Catalogue NumberOP128L
Brand Family Calbiochem®
SynonymsAnti-Promyelocytic Leukemia Zinc Finger
References
ReferencesYeyati, P.L., et al. 1999. Oncogene 18, 925.
Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
Li, J.Y., et al. 1997. Biol. Chem. 272, 22447.
Licht, J.D., et al. 1996. Oncogene 12, 323.
Avantaggiato, V., et al. 1995. J. Neurosci. 15, 4927.
Cook, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 2249.
Reid, A., et al. 1995. Blood 86, 4544.
Chen, Z., et al. 1993. EMBO. J. 12,1161.
Product Information
FormLyophilized
FormulationLyophilized from a volatile buffer, 100 µg BSA.
Negative controlHEK293 or CV-1 cells
Positive controlHL-60 or KG1 cells
PreservativeNone
Applications
Application ReferencesOriginal Clone Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
Key Applications Gel Shift
Immunoblotting (Western Blotting)
Immunofluorescence
Immunoprecipitation
Application NotesGel Shift (2 µg)
Immunoblotting (2 µg/ml)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg/ml)
Application CommentsPLZF, which migrates on SDS/PAGE as an ~81 kDa protein, is expressed at low levels in HL60 cells but at higher levels in myelodysplastic cells treated with the calcium ionophore A23187. Immunoprecipitation of PLZF from total cell lysate using Cat. No. OP128 followed by immunoblotting with Cat. No. OP128 can be used to detect low level expression of PLZF. The PLZF protein can be detected in human erythroleukemia cells and in CD34+ progenitor cells in addition to HL60 and KG1 cells. Anti-PLZF will also detect the PLZF-RARα fusion protein expressed in APL cells carrying the t(11;17)(q23;q21) translocation but not the RARα-PLZF fusion protein generated by the reciprocal translocation.(J. Licht, per. comm.). Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenpurified, recombinant, human PLZF fused to GST
ImmunogenHuman
Clone2A9
HostMouse
IsotypeIgG2a
Species Reactivity
  • Human
  • Mouse
  • Rat
Antibody TypeMonoclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Ok to freeze
Special InstructionsReconstitute the lyophilized antibody with 1 ml sterile H₂O, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage with 0.1% azide. Avoid freeze/thaw cycles of solutions.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
OP128L 0

Documentation

Anti-PLZF Mouse mAb (2A9) SDS

Title

Safety Data Sheet (SDS) 

Anti-PLZF Mouse mAb (2A9) Certificates of Analysis

TitleLot Number
OP128L

References

Reference overview
Yeyati, P.L., et al. 1999. Oncogene 18, 925.
Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
Li, J.Y., et al. 1997. Biol. Chem. 272, 22447.
Licht, J.D., et al. 1996. Oncogene 12, 323.
Avantaggiato, V., et al. 1995. J. Neurosci. 15, 4927.
Cook, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 2249.
Reid, A., et al. 1995. Blood 86, 4544.
Chen, Z., et al. 1993. EMBO. J. 12,1161.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision02-October-2007 RFH
SynonymsAnti-Promyelocytic Leukemia Zinc Finger
ApplicationGel Shift (2 µg)
Immunoblotting (2 µg/ml)
Immunofluorescence (2 µg/ml)
Immunoprecipitation (2 µg/ml)
DescriptionPurified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes to myeloma cells (see application references). Recognizes the ~81 kDa PLZF protein.
BackgroundThe promyelocytic leukemia zinc finger (PLZF) gene, first identified by its fusion with the RARα locus in a therapy resistant form of acute promyelocytic leukemia (APL) that is associated with the t(11;17)(q23;q21) translocation, encodes a 673 amino acid protein with nine Kruppel-like zinc fingers. PLZF is a sequence-specific DNA binding protein, highly conserved throughout vertebrate evolution, that is differentially expressed during embryogenesis and in adult tissues. The highest expression of PLZF occurs in multipotent, undifferentiated hematopietic progenitor cells and then declines following differentiation. PLZF is also expressed during development of the vertebrate hindbrain and may be critical for regulating boundary cell interactions. Recently, PLZF was shown to be a negative regulator of cell cycle progression capable of causing growth suppression leading to accumulation of cells in the G0/G1 stage of the cell cycle as well as a corresponding increased incidence of cells undergoing apoptosis. One target of PLZF is the cyclin A2 gene; PLZF can repress the cyclin A2 promoter and suppress growth while enforced expression of cyclin A2 reverts the growth suppressed phenotype of myeloid cells expressing PLZF. The RARα-PLZF fusion protein, generated in the t(11;17)(q23;q21)-form of APL, activates cyclin A2 transcription. Thus, inhibition of cyclin A2 expression may contribute to the growth suppressive properties of PLZF whereas deregulation of cyclin A2 by RARα-PLZF may represent an oncogenic mechanism of this chimeric protein. In addition to its role in hindbrain development, PLZF may contribute to the quiescent state of hematopoietic progenitor cells such that disruption of this activity in the therapy-resistant t(11;17)(q23;q21)-form of APL contributes to the drug-resistant character of this disease.
HostMouse
Immunogen speciesHuman
Immunogenpurified, recombinant, human PLZF fused to GST
Clone2A9
IsotypeIgG2a
Specieshuman, mouse, rat
Positive controlHL-60 or KG1 cells
Negative controlHEK293 or CV-1 cells
FormLyophilized
FormulationLyophilized from a volatile buffer, 100 µg BSA.
PreservativeNone
CommentsPLZF, which migrates on SDS/PAGE as an ~81 kDa protein, is expressed at low levels in HL60 cells but at higher levels in myelodysplastic cells treated with the calcium ionophore A23187. Immunoprecipitation of PLZF from total cell lysate using Cat. No. OP128 followed by immunoblotting with Cat. No. OP128 can be used to detect low level expression of PLZF. The PLZF protein can be detected in human erythroleukemia cells and in CD34+ progenitor cells in addition to HL60 and KG1 cells. Anti-PLZF will also detect the PLZF-RARα fusion protein expressed in APL cells carrying the t(11;17)(q23;q21) translocation but not the RARα-PLZF fusion protein generated by the reciprocal translocation.(J. Licht, per. comm.). Antibody should be titrated for optimal results in individual systems.
Storage +2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsReconstitute the lyophilized antibody with 1 ml sterile H₂O, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage with 0.1% azide. Avoid freeze/thaw cycles of solutions.
Toxicity Standard Handling
ReferencesYeyati, P.L., et al. 1999. Oncogene 18, 925.
Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.
Li, J.Y., et al. 1997. Biol. Chem. 272, 22447.
Licht, J.D., et al. 1996. Oncogene 12, 323.
Avantaggiato, V., et al. 1995. J. Neurosci. 15, 4927.
Cook, M., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 2249.
Reid, A., et al. 1995. Blood 86, 4544.
Chen, Z., et al. 1993. EMBO. J. 12,1161.
Application referencesOriginal Clone Shaknovich, R., et al. 1998 Mol. Cell Biol. 18, 5533.